Free Trial
NASDAQ:CGEN

Compugen (CGEN) Stock Price, News & Analysis

Compugen logo
$1.64
-0.07 (-4.09%)
(As of 11/4/2024 ET)

About Compugen Stock (NASDAQ:CGEN)

Key Stats

Today's Range
$1.63
$1.68
50-Day Range
$1.60
$2.10
52-Week Range
$0.53
$3.03
Volume
153,045 shs
Average Volume
176,741 shs
Market Capitalization
$146.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Buy

Company Overview

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Compugen Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
44th Percentile Overall Score

CGEN MarketRank™: 

Compugen scored higher than 44% of companies evaluated by MarketBeat, and ranked 644th out of 969 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Compugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Compugen has received no research coverage in the past 90 days.

  • Read more about Compugen's stock forecast and price target.
  • Earnings Growth

    Earnings for Compugen are expected to decrease in the coming year, from $0.15 to ($0.27) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Compugen is -16.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Compugen is -16.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Compugen has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Compugen's valuation and earnings.
  • Percentage of Shares Shorted

    1.74% of the outstanding shares of Compugen have been sold short.
  • Short Interest Ratio / Days to Cover

    Compugen has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in Compugen has recently decreased by 17.11%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Compugen does not currently pay a dividend.

  • Dividend Growth

    Compugen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.74% of the outstanding shares of Compugen have been sold short.
  • Short Interest Ratio / Days to Cover

    Compugen has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in Compugen has recently decreased by 17.11%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Compugen has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Compugen this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for CGEN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Compugen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Compugen insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.50% of the stock of Compugen is held by insiders.

  • Percentage Held by Institutions

    Only 12.22% of the stock of Compugen is held by institutions.

  • Read more about Compugen's insider trading history.
Receive CGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter.

CGEN Stock News Headlines

Compugen to Present New Clinical Data at SITC 2024
2 sentences that change everything you THOUGHT you knew about trading
If you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfast... go to work... But if you say these two sentences to your broker... you could collect as much as $1,250 on Friday... no matter where you live, whether you're working or already retired. It all has to do with a unique stock market secret that's worked 97% of the time for the past 8 years running.
Compugen Ltd
See More Headlines

CGEN Stock Analysis - Frequently Asked Questions

Compugen's stock was trading at $1.98 at the beginning of 2024. Since then, CGEN shares have decreased by 17.2% and is now trading at $1.64.
View the best growth stocks for 2024 here
.

Compugen Ltd. (NASDAQ:CGEN) released its earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.06. The biotechnology company had revenue of $6.70 million for the quarter, compared to the consensus estimate of $2.68 million.

Compugen's top institutional investors include Taylor Frigon Capital Management LLC (1.35%) and Joel Isaacson & Co. LLC (0.06%).

Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXDW), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL) and Block (SQ).

Company Calendar

Last Earnings
8/06/2024
Today
11/05/2024
Next Earnings (Confirmed)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CGEN
Employees
68
Year Founded
1993

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+143.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-18,750,000.00
Pretax Margin
-1.19%

Debt

Sales & Book Value

Annual Sales
$33.46 million
Book Value
$0.73 per share

Miscellaneous

Free Float
80,759,000
Market Cap
$146.35 million
Optionable
Optionable
Beta
2.64

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:CGEN) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners